A Study of Blood Based Biomarkers for Pancreas Adenocarcinoma
Recruiting now
Conditions studied: Pancreatic Cancer, Pancreatic Diseases, Pancreatitis, Pancreatic Cyst
In brief
The purpose of this study is to develop a minimally invasive test to diagnose pancreatic cancer at early stages of disease and monitor response to treatment.
Key facts
- Study ID
- NCT03334708
- Run by
- Memorial Sloan Kettering Cancer Center
- People needed
- 120
- Starts
- 2017-10-30
- Expected to finish
- 2026-10-30
- Last updated by the study team
- 2026-07-22
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: accepted.
You may qualify if…
- Cohort 1: Advanced Pancreatic Cancer Cohort Inclusion Criteria
- Radiological, histological or cytological confirmed diagnosis of locally advanced or metastatic pancreatic adenocarcinoma by the enrolling institution
- Patient planning to receive systemic treatment
- Hemoglobin > 8
- ECOG performance status 0-2
- A minimum age of 18 years old
- Willing to undergo a tumor biopsy
- Willing to provide permission to obtain banked tumor tissue for analysis (previous biopsies or surgical material).
- Cohort 2: Operable Pancreatic Cancer Cohort Inclusion Criteria
- Radiological, histological or cytological confirmed diagnosis of pancreatic adenocarcinoma by the enrolling institution
- Patient planned to undergo upfront resection
- No pre-operative systemic therapy nor chemoradiation therapy planned
- Hemoglobin > 8
- ECOG performance status 0-2
- A minimum age of 18 years old
- Willing to undergo a tumor biopsy
- Willing to provide permission to obtain banked tumor tissue for analysis (previous biopsies or surgical material).
- Cohort 3: Acute Benign Pancreatic Pathology Control Inclusion Criteria
- Confirmed diagnosis of acute pancreatitis or other acute pancreatic pathology by the enrolling institution
- Hemoglobin > 8
- ECOG performance status 0-2
- A minimum age of 18 years old
- Cohort 4: Chronic Benign Pancreatic Pathology Control Inclusion Criteria
- Confirmed diagnosis of chronic pancreatitis or other non-cystic chronic pancreatic pathology by the enrolling institution
- Hemoglobin > 8
You may not qualify if…
- Cohort 1: Advanced Pancreatic Cancer Cohort Exclusion Criteria
- Prior chemotherapy or radiation therapy for pancreatic cancer within the last 3 months in the localized setting
- Active second malignancy, unless low grade malignancy
- Any medical or psychiatric condition that may interfere with ability to comply with protocol procedures
- Cohort 2: Operable Pancreatic Cancer Cohort Exclusion Criteria
- Neoadjuvant chemotherapy or radiation therapy is planned
- Active second malignancy, unless low grade malignancy
- Any medical or psychiatric condition that may interfere with ability to comply with protocol procedures
- Cohort 3: Acute Benign Pancreatic Pathology Control Exclusion Criteria
- Active or prior malignancy, except prior non-melanoma skin cancer
- Proven to be a carrier of a cancer susceptibility gene or family history concerning for genetic predisposition to cancer
- Any medical or psychiatric condition that may interfere with ability to comply with protocol procedures
- Cohort 4: Chronic Benign Pancreatic Pathology Control Exclusion Criteria
- Active or prior malignancy, except prior non-melanoma skin cancer
- Proven to be a carrier of a cancer susceptibility gene or family history concerning for genetic predisposition to cancer
- Any medical or psychiatric condition that may interfere with ability to comply with protocol procedures
- Cohort 5: IPMN Control Exclusion Criteria
- IPMN with high risk features or planned resection
- Active or prior malignancy, except prior non-melanoma skin cancer
- Proven to be a carrier of a cancer susceptibility gene or family history concerning for genetic predisposition to cancer
- Any medical or psychiatric condition that may interfere with ability to comply with protocol procedures
- Cohort 6: Pancreatic Cyst Control Exclusion Criteria
- Active or prior malignancy, except prior non-melanoma skin cancer
- Proven to be a carrier of a cancer susceptibility gene or family history concerning for genetic predisposition to cancer
- Any medical or psychiatric condition that may interfere with ability to comply with protocol procedures
Where it is running
- Sheba Medical Center — Tel Litwinsky, Israel (enrolling)
- Memorial Sloan Kettering Bergen (All protocol activities) — Montvale, New Jersey, United States (enrolling)
- Memorial Sloan Kettering Westchester (All protocol activities) — Harrison, New York, United States (enrolling)
- Memorial Sloan - Kettering Cancer Center — New York, New York, United States (enrolling)
- Memorial Sloan Kettering Basking Ridge (All protocol activities) — New York, New York, United States (enrolling)
- Memorial Sloan Kettering Nassau (All protocol activities) — Rockville Centre, New York, United States (enrolling)
- Memorial Sloan Kettering Monmouth (All protocol activities) — Middletown, New Jersey, United States (enrolling)
- Memorial Sloan Kettering Cancer Center @ Commack (All Protocol Activities) — Commack, New York, United States (enrolling)
- Cold Springs Harbor Laboratory (Specimen Analysis) — Cold Spring Harbor, New York, United States
- Sha'are Zedek Medical Center — Jerusalem, Israel
- Weill Cornell Medical Center — New York, New York, United States
- New York University — New York, New York, United States
- Weizmann Institute of Science — Rehovot, Israel
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.